Lead Product(s) : Rufinamide
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai Satisfies All-case Study Requirement For Antiepileptic Agent Inovelon®
Details : Inovelon (rufinamide) is triazole derivative,believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in brain involved in overexcitement of neurons that potentially causes seizures, so as to prolong their inact...
Product Name : Inovelon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Rufinamide
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adalimumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie, Eisai Receives Approval for Additional Indication of Humira to Treat Pyoderma Gangrenosum
Details : Approval is based on the data from a Japanese phase III clinical trial. The proportion of patients achieving at 100 of the target pyoderma gangrenosum ulcer area reduction at Week 26 of Humira administration was 54.5% in the trail.
Product Name : Humira
Product Type : Antibody
Upfront Cash : Inapplicable
November 27, 2020
Lead Product(s) : Adalimumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
